TY - JOUR
T1 - Comparison of the effects of aminosugar cardiac glycosides wth ouabain and digoxin on Na+, K+ adenosine triphosphatase and cardiac contractile force
AU - Caldwell, R. W.
AU - Nash, C. B.
PY - 1978
Y1 - 1978
N2 - Two aminosugar cardiac glycosides, 3-β-O-(4-amino-4,6-dideoxy-β-D-galactopyranosyl) digitoxigenin (ASI-222) and its 4-aminoglucose analog (ASI-254) have been shown in our laboratory to have a greater therapeutic index than ouabain (O) or digoxin (D). We have now compared the ability of ASI-222, its nonamino galactose analog (ASI-253), ASI-254, ouabain and digoxin to inhibit swine brain Na+,K+-adenosine triphosphatase (Na+,K+-ATPase) and to increase contractile force of isolated, driven rabbit atria. As inhibitors of Na+,K+-ATPase, both ASI-222 and ASI-254 were found to be about 10 times more potent than ASI-253, O or D (I50: ASI-222, 1.3 x 10-7 M; ASI-254, 1.4 x 10-7 M; ASI-253, 1.15 x 10-6 M; D, 1.6 x 10-6 M; O, 1.75 x 10-6 M). Moreover, the potency of these glycosides in inhibiting Na+,K+-ATPase correlates closely with the ability of these same glycosides to increase contractile force. The concentration needed to obtain 50% of the maximum increase in contractile force was 9.7 x 10-8 M for ASI-254, 1.5 x 10-7 M for ASI-222, 8.8 x 10-7 M for ASI-253, 8.4 x 10-7 M for O and 1.2 x 10-6 M for D. Since ASI-253, a nonaminogalactose analog of ASI-222, exhibits a potency in both of our test systems which is similar to the other neutral sugar cardenolides our data also indicate that the presence of an aminosugar group at position 4 of a sugar in a cardiac glycoside confers greater potency.
AB - Two aminosugar cardiac glycosides, 3-β-O-(4-amino-4,6-dideoxy-β-D-galactopyranosyl) digitoxigenin (ASI-222) and its 4-aminoglucose analog (ASI-254) have been shown in our laboratory to have a greater therapeutic index than ouabain (O) or digoxin (D). We have now compared the ability of ASI-222, its nonamino galactose analog (ASI-253), ASI-254, ouabain and digoxin to inhibit swine brain Na+,K+-adenosine triphosphatase (Na+,K+-ATPase) and to increase contractile force of isolated, driven rabbit atria. As inhibitors of Na+,K+-ATPase, both ASI-222 and ASI-254 were found to be about 10 times more potent than ASI-253, O or D (I50: ASI-222, 1.3 x 10-7 M; ASI-254, 1.4 x 10-7 M; ASI-253, 1.15 x 10-6 M; D, 1.6 x 10-6 M; O, 1.75 x 10-6 M). Moreover, the potency of these glycosides in inhibiting Na+,K+-ATPase correlates closely with the ability of these same glycosides to increase contractile force. The concentration needed to obtain 50% of the maximum increase in contractile force was 9.7 x 10-8 M for ASI-254, 1.5 x 10-7 M for ASI-222, 8.8 x 10-7 M for ASI-253, 8.4 x 10-7 M for O and 1.2 x 10-6 M for D. Since ASI-253, a nonaminogalactose analog of ASI-222, exhibits a potency in both of our test systems which is similar to the other neutral sugar cardenolides our data also indicate that the presence of an aminosugar group at position 4 of a sugar in a cardiac glycoside confers greater potency.
UR - http://www.scopus.com/inward/record.url?scp=0017883367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017883367&partnerID=8YFLogxK
M3 - Article
C2 - 145490
AN - SCOPUS:0017883367
SN - 0022-3565
VL - 204
SP - 141
EP - 148
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -